O
ESPR

OrbiMed’s Esperion Therapeutics ESPR Stock Holding History

OrbiMed’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,570,300
Closed -$29M – 139
2026
Q1 		$29M Buy
10,570,300
+4,604,802
+77% +$14.6M 0.57% 49
2025
Q4 		$22.1M Buy
+5,965,498
New +$19.3M 0.45% 56
2024
Q2 		– Sell
-13,708,731
Closed -$36.7M – 121
2024
Q1 		$36.7M Buy
+13,708,731
New +$33.3M 0.67% 46
2013
Q4 		– Sell
-60,800
Closed -$1.15M – 129
2013
Q3 		$1.15M Buy
+60,800
New +$1.02M 0.02% 124

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

OrbiMed's ESPR Position: Q2 2026 in Review

OrbiMed sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 10,570,300 shares — an estimated $29M sold.

OrbiMed first reported a position in ESPR in Q3 2013 and held it in 4 quarters. The position peaked at $36.7M in Q1 2024. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • OrbiMed reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • OrbiMed sold 10,570,300 Esperion Therapeutics shares in Q2 2026, an estimated $29M.
  • OrbiMed first reported a position in Esperion Therapeutics in Q3 2013 and held it in 4 quarters.
  • OrbiMed's Esperion Therapeutics position peaked at $36.7M in Q1 2024.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.